| ORIGINAL ARTICLE |
|
| Year : 2021 | Volume
: 10
| Issue : 1 | Page : 5-10 |
|
|
Serum level of programmed death-ligand 1 in patients with gastric cancer in Mazandaran Province as a High-Risk Region in Iran
Ramin Shekarriz, Akbar Hedayatizadeh-Omran, Omolbanin Amjadi, Reza Alizadeh-Navaei, Gholamali Godazandeh
Gastrointestinal Cancer Research Center, Non-Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran
Correspondence Address:
Akbar Hedayatizadeh-Omran
Gastrointestinal Cancer Research Center, Non-Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari
Iran
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ccij.ccij_128_20
|
|
|
Background: Gastric cancer is one of the most common cancers in the world. Programmed death-ligand 1 (PD-L1) is the main ligand of the programmed death-1 receptor that plays a key role in apoptosis in patients with gastric cancer. Materials and Methods: In this study, forty gastric cancer patients and forty healthy controls were enrolled. Serum PD-L1 was measured by enzyme-linked immunosorbent assay. Results: The mean (interquartile range) value of expression level of PD-L1 was 70.6 (36.6–127.3) in patients and 47.7 (29.9–92.1) in controls. There were no significant differences in PD-L1 expression between the two groups and tumor characteristics, but there was a statistically significant difference between the high expression level of PD-L1 and gastric cancer development (P = 0.044, odds ratio = 2.77, 95% confidence interval = 1.12–6.86). Conclusions: PD-L1 level increases in gastric cancer patients, so it could be used as a predictor factor.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
